The prognostic significance of tryptophanyl-tRNA synthetase in colorectal cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 11, 2009, Pages 2949-2956

  Ghanipour, Arezo ^a   Jirström, Karin ^d   Pontén, Fredrik ^b   Glimelius, Bengt ^c,e   Påhlman, Lars ^a   Birgisson, Helgi ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d LUND UNIVERSITY   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID TRANSFER RNA LIGASE; CARCINOEMBRYONIC ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; POLYCLONAL ANTIBODY; TRYPTOPHAN;

AGED; ANTIANGIOGENIC ACTIVITY; ARTICLE; CALCULATION; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; COHORT ANALYSIS; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE FREE SURVIVAL; HAZARD RATIO; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPH VESSEL; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; POPULATION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; RISK FACTOR; RISK REDUCTION; TISSUE MICROARRAY; TUMOR CELL; TUMOR DIFFERENTIATION;

CARCINOEMBRYONIC ANTIGEN; CELL DIFFERENTIATION; COHORT STUDIES; COLORECTAL NEOPLASMS; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPH NODES; LYMPHATIC METASTASIS; MUCOUS MEMBRANE; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TRYPTOPHAN-TRNA LIGASE;

EID: 72749124936     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-09-0456     Document Type: Article

References (35)

1. International Union Against Cancer (UICC). Prognostic factors in cancer. Berlin, Heidelberg, New York: Springer; 1995.
2. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update recommendations for the use of tumor makers in gastrointestinal cancer. J Clin Oncol 2006;24:5313-5327
3. Zlobec I, Lugli A. Prognostic and predictive factors in colorectal cancer. J Clin Pathol 2008;61:561-569 (Pubitemid 351688621)
4. Uhlén M, Björling E, Agaton C, et al. A human atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteomics 2005;4:1920-1932 (Pubitemid 41830186)
5. Nilsson P, Paavilainen L, Larsson K, et al. Towards a human proteome atlas: high-throughput generation of mono-specific antibodies for tissue profiling. Proteomics 2005;5:4327-4337 (Pubitemid 41739911)
6. Björling E, Lindskog C, Oksvold P, et al. Aweb-based tool for in silico biomarker discovery based on tissue-specific protein profiles in normal and cancer tissues. Mol Cell Proteomics 2008;7:825-844 (Pubitemid 351737085)
7. Pontén F, Jirström K, Uhlen M. The Human Protein Atlas-a tool for pathology. J Pathol 2008;216:387-393
8. Wakasugi K, Schimmel P. Two distinct cytokines released from a human aminoacyl-tRNA synthetase. Science 1999;284:147-151 (Pubitemid 29282068)
9. Aboagye-Mathiesen G, Ebbesen P, von der Maase H, Celis JE. Interferon γ regulates a unique set of proteins in fresh bladder transitional cell carcinomas. Electrophoresis 1999;20:344-348 (Pubitemid 29125021)
10. Yang XL, Guo M, Kapoor M, et al. Functional and crystal structure analysis of active site adaptions of a potent anti-angiogenic human tRNA synthetase. Structure 2007;15:793-805. (Pubitemid 47049681)
11. Otani A, Slike BM, Dorell MI, et al. A fragment of human TrpRS as a potent antagonist of ocular angiogenesis. Proc Natl Acad Sci U S A 2002;99:178-183 (Pubitemid 34060337)
12. Tzima E, Reader JS, Irani-Tehrani M, Ewalt KL, Schwartz MA, Schimmel P. VE-cadherin links tRNA synthetase cytokine to antiangiogenic function. J Biol Chem 2005;280:2405-2408 (Pubitemid 40189338)
13. Tzima E, Schimmel P. Inhibition of tumor angiogenesis by a natural fragment of a tRNA synthetase. Trends Biochem Sci 2006;31:7-10. (Pubitemid 43117534)
14. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-847 (Pubitemid 28331029)
15. Compton CC, Fieding LP, Burgart LJ, et al. Prognostic factors in colorectal cancer. College of American Pathologists consensus statement 1999. Arch Pathol Lab Med 2000;124:979-994
16. Punt CJ, Buyse M, Köhne CH, et al. Endpoints in adjuvant trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst 2007;99:998-1003. (Pubitemid 47232601)
17. Sturgeon CM, Duffy MJ, Stenman UH, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008;54:e11-79.
18. Hara M, Kanemitsu Y, Hirai T, Komori K, Kato T. Negative serum carcinoembryonic antigen has insufficient accuracy for excluding recurrence from patients with Dukes Cc olorectal cancer: analysis with likelihood ratio and posttest probability in a follow-up study. Dis Colon Rectum 2008;51:1675-1680
19. Wakasugi K, Slike BM, Hood J, et al. A human aminoacyl-tRNA synthetase as a regulator of angiogenesis. Proc Natl Acad Sci U S A 2002; 99:173-177 (Pubitemid 34060336)
20. Zhou Q, Kiosses W, Liu J, Schimmel P. Tumor endothelial cell tube formation model for determining anti-angiogenic activity of a tRNA synthetase cytokine. Methods 2008;44:190-195 (Pubitemid 351172810)
21. Jakobsson L, Claesson-Welsh L. Vascular basement membrane components in angiogenesis-an act of balance. Scientific World Journal 2008;8:1246-1249
22. Szekanecz Z, Koch AE. Vascular involment in rheumatic diseases: vascular rheumatology. Arthritis Res Ther 2008;10:224.
23. Nyberg PST, Kalluri R. Tumor microenvironment and angiogenesis. Front Biosci 2008;13:6537-6553
24. Abrahám-Marin ML, Cortés-Luna CF, Alvarez-Rivera G, Hernández- Rojas M, Quiroz-Mercado H, Morales-Cantón V. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration: a pilot study. Clin Exp Ophtalmol 2007;245:651-655 (Pubitemid 46951230)
25. Jestin P, Påhlman L, Glimelius B, Gunnarsson U. Cancer staging and survival in colon cancer is dependent on the quality of the pathologists' specimen examination. Eur J Cancer 2005;41:2071-2078 (Pubitemid 41337948)
26. Kyndi M, Sørensen FB, Knudsen H, et al. Tissue microarrays compared with whole sections and biochemical analysis. A subgroup analysis of DBCG 82 b&c. Acta Oncol 2008;47:591-599
27. George ML, Tutton MG, Janssen F, et al. VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression. Neoplasia 2001;3:420-427
28. Hanrahan V, Currie MJ, Gunningham SP, et al. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. J Pathol 2003;200:183-194 (Pubitemid 36748027)
29. Folkman. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-1186
30. Folkman. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972;175:409-416
31. Lee JC, Chow NH, Wang ST, Huang SM. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 2000;36:748-753 (Pubitemid 30179746)
32. Takahashi Y, Kiitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995;55:3964-3968
33. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005;23:3502-3508 (Pubitemid 46243494)
34. Rhaman-Roblick R, Roblick UJ, Hellman U, et al. p53 targets identified by protein expression profiling. Proc Natl Acad Sci U S A 2007;104:5401-5406 (Pubitemid 47175692)
35. Takahashi Y, Bucana CD, Cleary KR, Ellis LM. p53, vessel count, and vascular endothelial growth factor expression in human colon cancer. Int J Cancer 1998;79:34-38 (Pubitemid 28157723)